We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Adaptive Treatment for Adolescent Cannabis Use Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01656707
Recruitment Status : Completed
First Posted : August 3, 2012
Last Update Posted : April 11, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to examine an Adaptive Treatment approach in order to improve outcomes of youth with Cannabis Use Disorders who are poor responders to treatment.

Condition or disease Intervention/treatment
Mental Disorders Addictive Behaviors Cannabis Use Disorder Behavioral: ACRA Behavioral: CBT

Detailed Description:

The study will address the current contrasts in youth response to treatment, the problem of poor response to treatment and the prevention of relapse. Results from the study may support Adaptive Treatment as an efficacious approach for youth with Cannabis Use Disorder who are poor responders to treatment.

Poor responders fall into two categories, those who failed to achieve a negative drug urinalysis during the last session of the initial MET/CBT-7 treatment they attended, and those who either dropped out or were administratively discharged at any time during the initial MET/CBT-7 treatment.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 172 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adaptive Treatment for Adolescent Cannabis Use Disorders
Study Start Date : September 2011
Primary Completion Date : July 2016
Study Completion Date : July 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: ACRA
Ten weekly 60-minute sessions of Adolescent Community Reinforcement Approach (ACRA) will be provided as an Adaptive treatment condition.
Behavioral: ACRA
Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
Other Name: Adolescent Community Reinforcement Approach
Experimental: Cognitive Behavioral Therapy (CBT)
Ten weekly, 60-minute sessions of augmented individualized Cognitive Behavioral Therapy (CBT)will be provided as an Adaptive Treatment condition
Behavioral: CBT
10 weekly, 60-minute sessions of augmented individualized CBT
Other Name: Cogntive Behavioral Therapy

Outcome Measures

Primary Outcome Measures :
  1. 1.) To evaluate the efficacy of AT for youth who have been defined as poor responders to an evidence-based practice intervention such as the initial MET/CBT-7. [ Time Frame: one year ]
    Each participant will serve as his/her own control. The outcomes will include the T-ASI, T-ASI-P, and drug urinalyses.

Secondary Outcome Measures :
  1. To assess outcomes as a function of mediator variables such as self-efficacy, coping skills, readiness to change, and environmental support (i.e., family and peer), within each of the AT interventions. [ Time Frame: one year ]
    The secondary outcome measures will include the SCQ, CRI, PRQ, and SSQ.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   13 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 13-18 years of age at the time of intake assessment
  • Current diagnosis of DSM-IV Cannabis Abuse or Dependence
  • Able to read and comprehend English at a 5th grade level
  • Residence within 45 minutes drive from the UCHC Farmington treatment site
  • Participant and a parent/legal guardian responsible for providing collateral information agree to sign an IRB approved consent form
  • Participant and a parent/legal guardian responsible for providing collateral information agree to provide locator information
  • The family is not planning to move from the area during the next six months

Exclusion Criteria:

  • Meet criteria for dependence of any other substance of abuse other than nicotine or alcohol
  • Report suicidal ideation with a plan, suicidal behavior, a plan to hurt oneself or other, or a history of self-injurious behavior all occurring in the last 30 days
  • Meet a lifetime diagnosis of schizophrenia
  • Has any current health (i.e. medical, psychiatric) condition that will compromise the participant's ability to regularly attend treatment
  • Demonstrate an inability or unwillingness to provide locator information
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01656707

United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030-2103
Sponsors and Collaborators
UConn Health
National Institute on Drug Abuse (NIDA)
Principal Investigator: Yifrah Kaminer, MD, MBA UConn Health
More Information

Responsible Party: UConn Health
ClinicalTrials.gov Identifier: NCT01656707     History of Changes
Other Study ID Numbers: PA08-263
R01DA030454 ( U.S. NIH Grant/Contract )
First Posted: August 3, 2012    Key Record Dates
Last Update Posted: April 11, 2017
Last Verified: April 2017

Keywords provided by UConn Health:
Substance Use Disorders

Additional relevant MeSH terms:
Marijuana Abuse
Mental Disorders
Psychotic Disorders
Behavior, Addictive
Pathologic Processes
Substance-Related Disorders
Chemically-Induced Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Compulsive Behavior
Impulsive Behavior